In Vitro and In Vivo Assessment of Hepatic and Extrahepatic Metabolism of Diazepam in the Rat

doi:10.1002/jps.2600730631

Journal of Pharmaceutical Sciences

Volume 73, Issue 6, June 1984, Pages 826-828

https://doi.org/10.1002/jps.2600730631 Get rights and content

Abstract

Since diazepam is metabolized by many organs in the rat, the microsomal fractions of the liver, kidney, and lung from male Wistar rats were assayed for NADPH‐dependent metabolism of diazepam and enzymatic parameters. The predicted extraction ratios were obtained from this in vitro experimental system. The organ clearances of the liver, kidney, and lung were then calculated for the determination of the relative contribution of each eliminating organ to the total body clearance (CL_tot) of diazepam in the rat. The liver was the most effective eliminating organ, followed by the kidney and the lung, in that order. The hepatic extraction ratio of diazepam was determined in vivo after portal and femoral vein administrations of diazepam. The validity of the in vitro experimental system for the liver was demonstrated by a good agreement between the calculated hepatic extraction ratio of diazepam from in vitro enzymatic parameters (0.616) and that derived in vivo (0.648). However, the sum of organ clearances of the liver, kidney, and lung did not account for CL_tot of diazepam in the rat, suggesting the possible contribution of the metabolism in the other organs or tissues, or an underestimation of the pulmonary and renal metabolism.

REFERENCES (34)

I.A. Zingales
J. Chromatogr.
(1973)
J.A.F. de Silva et al.
J. Pharm. Sci.
(1966)
J.H. Lin et al.
Biochem. Pharmacol.
(1980)
E. Schlede et al.
Life. Sci.
(1970)
G. Feuer et al.
Toxicol Appl. Pharmacol.
(1971)
M. Rowland et al.
J. Pharm. Sci.
(1972)
R.L. Dedrick et al.
Biochem. Pharmacol.
(1972)
R.L. Dedrick et al.
J. Pharm. Sci.
(1973)
U. Klotz et al.
J. Pharmacol. Exp. Ther.
(1976)
U. Klotz et al.
J. Clin. Invest.
(1975)

C.L. Litterst et al.

Drug Metab. Dispos.

(1975)

Y. Igari et al.

Drug Metab. Dispos.

(1982)

Y. Igari et al.

J. Pharmacokinet. Biopharm.

(1982)

M.A. Schwartz et al.

J. Pharmacol. Exp. Ther.

(1965)

J.A.F. de Silva et al.

Fed. Proc.

(1966)

T. Nakagawa et al.

"SALS, a Computer Program for Statistical Analysis with Least-Squares Fitting,"

(1978)

A. Rane et al.

J. Pharmacol. Exp. Ther.

(1977)

Cited by (28)

The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model
2017, Journal of Pharmaceutical Sciences
Citation Excerpt :
The Rodgers and Rowland method predicts Vss within 1.5-fold (5.2 L/kg observed vs. predicted 3.63 L/kg). It should be noted that the observed data were obtained from a pharmacokinetic study in Wistar rats.28 Three doses of i.v. administered metoprolol (0.5, 1, and 2 mg/kg) were simulated and compared with observed data29 (Fig. 2).
The use of in vitro–in vivo extrapolation (IVIVE) techniques, mechanistically incorporated within physiologically based pharmacokinetic (PBPK) models, can harness in vitro drug data and enhance understanding of in vivo pharmacokinetics. This study’s objective was to develop a user-friendly rat (250 g, male Sprague–Dawley) IVIVE-linked PBPK model. A 13-compartment PBPK model including mechanistic absorption models was developed, with required system data (anatomical, physiological, and relevant IVIVE scaling factors) collated from literature and analyzed. Overall, 178 system parameter values for the model are provided. This study also highlights gaps in available system data required for strain-specific rat PBPK model development. The model’s functionality and performance were assessed using previous literature–sourced in vitro properties for diazepam, metoprolol, and midazolam. The results of simulations were compared against observed pharmacokinetic rat data. Predicted and observed concentration profiles in 10 tissues for diazepam after a single intravenous (i.v.) dose making use of either observed i.v. clearance (CL_iv) or in vitro hepatocyte intrinsic clearance (CL_int) for simulations generally led to good predictions in various tissue compartments. Overall, all i.v. plasma concentration profiles were successfully predicted. However, there were challenges in predicting oral plasma concentration profiles for metoprolol and midazolam, and the potential reasons and according solutions are discussed.
Prediction of the maximal tolerated dose (MTD) and therapeutic effect of anticancer drugs in humans: integration of pharmacokinetics with pharmacodynamics and toxicodynamics
1995, Cancer Treatment Reviews
Pharmacokinetics of diazepam in the rat: Influence of a carbon tetrachloride‐induced hepatic injury
1992, Journal of Pharmaceutical Sciences
The pharmacokinetics of diazepam in normal rats and in rats pretreated with carbon tetrachloride to induce hepatic cirrhosis (cirrhotic rats) was studied after intravenous and oral administration of the drug (4 mg/kg). Animals pretreated with this hepatotoxic agent showed a significant prolongation in the half-life of diazepam in plasma that is due more to an increase in volume of distribution rather than to a decrease in clearance. This study confirmed that diazepam was highly extracted by the rat liver and was not affected by the hepatotoxic agent, although there probably was a saturation of the activity of the cytochrome P₄₅₀ enzyme when the drug was administered orally. Diazepam binds to plasma proteins to a high degree in both normal and cirrhotic rats; however, in the latter, a significant increase in the fraction of unbound drug in plasma was observed. Pretreatment of rats with carbon tetrachloride did not produce any change either in the distribution of diazepam into erythrocytes or in the disposition of the metabolite desmethyldiazepam.
Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats
1989, Biochemical Pharmacology
Pharmacokinetic study of human epidermal growth factor (hEGF) in rats was performed in vivo. The hepatic extraction ratio (E_H) of [¹²⁵I]hEGF, determined from the difference between the artery and the hepatic vein plasma concentrations at steady state, was 0.19. The hepatic clearance (CL_H: 7.56 ml/min/kg body wt), calculated by multiplying (E_H) by the hepatic plasma flow rate (Q_P,H), was approximately 70% of the total body clearance (CL_tot: 10.8 ml/min/kg body wt), which was determined from the steady-state arterial plasma concentration and the infusion rate. These results indicated that the liver is the main organ responsible for the removal of [¹²⁵I]hEGF from the systemic circulation in rats. The renal extraction ratio (E_R) of [¹²⁵I]hEGF was half of that of [¹⁴C]inulin; this may have resulted from the plasma protein binding of [¹²⁵I]hEGF, which was approximately 50% as determined by the charcoal adsorption method and the equilibrium gel-filtration method. The renal clearance (CL_R: 2.65 ml/min/kg body wt), calculated by multiplying E_R by the renal plasma flow rate (Q_PR), was approximately 17% of the CL_tot- (15.6 ml/min/kg body wt), indicating a minor contribution of CL_R. to CL_tot compared with that of CL_H to CL_tot. The CL_R of [¹²⁵I]hEGF calculated from the urinary excretion data was one-tenth of that calculated from the plasma concentration difference between the femoral artery and the renal vein at steady state. These results suggest that the bulk of [¹²⁵I]hEGF cleared from the plasma by the kidney may have been metabolized further in the renal tubules before appearing in the urine.
Man versus beast: Pharmacokinetic scaling in mammals
1986, Journal of Pharmaceutical Sciences
Land mammals range in size from the 3-g shrew to the 3000-kg elephant. Despite this 10⁶ range in weight, most land mammals have similar anatomy, physiology, biochemistry, and cellular structure. This similarity has allowed interspecies scaling of physiologic properties such as heart rate, blood flow, blood volume, organ size, and longevity. The equation that is the basis for scaling physiologic properties among mammals is the power equation Y = aW^b, where Y is the physiologic variable of interest, W is body weight, and log a is the y-intercept and b is the slope obtained from the plot of log Y versus log W. Animals commonly used in preclinical drug studies (i.e., mice, rats, rabbits, monkeys, and dogs) do not eliminate drugs at the same rate that humans eliminate drugs; small mammals usually eliminate drugs faster than large mammals. Since drug elimination is intimately associated with physiologic properties that are well described among species, it seems reasonable to surmise that drug elimination can be scaled among mammals. Analysis of drug pharmacokinetics in numerous species demonstrates that drug elimination among species is predictable and, in general, obeys the power equation Y = aW^a. Early papers on interspecies pharmacokinetic scaling normalized the x- and y-axes to illustrate the superimposability of pharmacokinetic curves from different species. More recently, the x- and y-axes have been left in the common units of concentration and time, and individual pharmacokinetic variables have been adjusted to predict pharmacokinetic profiles in an untested species, usually humans.
A Simulation study on the effect of a uniform diffusional barrier across hepatocytes on drug metabolism by evenly or unevenly distributed uni‐enzyme in the liver
1986, Journal of Pharmaceutical Sciences
The effect of a uniform diffusional barrier on hepatic extraction of the parent drug by evenly or unevenly distributed unienzyme was quantitatively determined by the present simulation study. Five models of enzymic distribution were defined with regard to the hepatic blood flow path, and the extraction ratios were calculated or simulated under the various conditions of average intrinsic clearances and diffusion clearances across hepatocytes. Differences in the extraction ratios among the five models were evaluated by the “relative extraction ratios,” which are the extraction ratios in each model divided by that in the model where the enzymatic activity is evenly distributed. It was found that when a diffusion clearance was high compared to the intrinsic clearance, enzymic distribution was not an Important determinant of the extent of hepatic extraction. By contrast, when a diffusional barrier across hepatocytes exists, i.e., the diffusion clearance is low or intermediate compared to the intrinsic clearance, extraction ratios differed widely among the models of enzymic distribution, especially at intermediate average intrinsic clearances. In the presence of a diffusional barrier, the more skewed the distribution of the enzymatic activity is, the lesser the amount of drug eliminated at steady state. The most efficient metabolism occurred when the enzymatic activity was evenly distributed.

View all citing articles on Scopus

View full text

NOTESIn Vitro and In Vivo Assessment of Hepatic and Extrahepatic Metabolism of Diazepam in the Rat

Abstract

J. Chromatogr.

J. Pharm. Sci.

Biochem. Pharmacol.

Life. Sci.

Toxicol Appl. Pharmacol.

J. Pharm. Sci.

Biochem. Pharmacol.

J. Pharm. Sci.

J. Pharmacol. Exp. Ther.

J. Clin. Invest.

Drug Metab. Dispos.

Drug Metab. Dispos.

J. Pharmacokinet. Biopharm.

J. Pharmacol. Exp. Ther.

Fed. Proc.

"SALS, a Computer Program for Statistical Analysis with Least-Squares Fitting,"

J. Pharmacol. Exp. Ther.

NOTES
In Vitro and In Vivo Assessment of Hepatic and Extrahepatic Metabolism of Diazepam in the Rat